Faced with the failure of current treatments for the most aggressive brain tumours, a team from Grenoble and Marseille in France has unveiled an innovative dual therapy combining two generic cancer drugs, mebendazole and bumetanide. The first kills cancer cells and the second blocks hyperactivity and metastasis. The combination has been patented by B&A-Oncomedical, a … Continue reading A combination of two generic cancer drugs to treat brain tumours: preclinical results and compassionate use trial